Phathom













































































The lack of confidence is short sighted and surprising. This drug is already taking off in certain areas and launch just started. It will be a blockbuster if given time.

I am not aware of any 'areas' this drug is taking off in. Certainly not the two Hp products. And does anyone wonder why Takeda just didn't launch PCAB in US? I assume it is because their market analysis showed it was a very risky venture. US market is flooded with cheap OTC PPIs; how is a PCAB going to compete with this?